Anticancer therapy in patients with porphyrias: evidence today

作者：Thiery Vuillemin Antoine^*; Chaigneau Loic; Meaux Ruault Nadine; Villanueva Cristian; N'guyen Thierry; Maurina Tristan; Stein Ulrich; Lorgis Veronique; Demarchi Martin; Pivot Xavier

来源：Expert Opinion on Drug Safety, 2008, 7(2): 159-165.

DOI：10.1517/14740338.7.2.159

• aromatase inhibitor
• breast
• cancer
• chemotherapy
• docetaxel
• growth factor
• porphyria

Background: Porphyrias are rare diseases, and for these patients every administration of drugs may induce an acute attack of porphyria. The list of safe compounds allowed in these patients is available for clinicians from specific websites cited in the text. Objectives: However, data concerning anticancer therapy in patients with such diseases remain poor. Therefore any publications can help clinicians to deal with this very specific group of patients. Methods: In our institution, three patients received docetaxel and hematologic growth factors (erythropoietin and GCSF) without unexpected toxicities. Aromatase inhibitors (anstrozole and letrozole) were also given in one patient without any related problem. Conclusion: The present observation adds some useful data for the possible treatment of cancer in patients with porphyria.

• 出版日期2008-3